Skip to main content
Top
Published in: Indian Journal of Gastroenterology 2/2019

01-04-2019 | Cardiomyopathy | Original Article

Prevalence and clinical presentation of cirrhotic cardiomyopathy: A single centre experience from southern India

Authors: Ravi Bokarvadia, Mayank Jain, Chandankumar Kedarisetty, Joy Varghese, Jayanthi Venkataraman

Published in: Indian Journal of Gastroenterology | Issue 2/2019

Login to get access

Abstract

Background

There are scanty data from India on the prevalence and clinical profile of cirrhotic cardiomyopathy (CCM).

Aim

To identify the prevalence and clinical presentation of CCM in patients with liver cirrhosis.

Methods

Five hundred and eighty-six patients with liver cirrhosis were recruited based on inclusion criteria and evaluated for cardiac parameters using electrocardiography, 2-dimensional echocardiography, dobutamine stress test and coronary angiography as needed. Baseline demographic data, liver biochemistry, endoscopic and radiological findings were recorded in all the patients. Appropriate statistical analyses were performed. 

Results

Four thousand eight hundred and seventy-seven patients with liver disease were registered during the study period. Five hundred and eighty-six cirrhotic patients had cardiac evaluation as per the study protocol. One hundred fifty-nine had coronary artery disease and were excluded. One hundred and ninety-eight of 427 remaining patients (46.4%) had CCM. The median age of patients with CCM was higher compared with those without CCM (52 years vs. 46 years; p-value < 0.00001). Likewise, cirrhosis-related complications ([isolated or in combination], lower pulse rate [< 60/min] and prolonged corrected QT interval [QTc]; p<0.00001) were more frequent in patients with CCM. After excluding known risk factors for CCM such as alcohol, diabetes, hypothyroidism, hypertension, the true prevalence of CCM was 8.2% (48 out of 586). Hepatotropic viral infections (p 0.03) and prolonged QTc (p 0.0004) were commoner in CCM.

Conclusion

Prevalence of CCM in our setting is 33.8%. CCM is commoner in males and is independent of the etiology of cirrhosis, comorbidity and severity of liver disease. Diastolic dysfunction and prolonged QTc interval are common in CCM.
Literature
1.
go back to reference Kowalski HJ, Abelmann WH. The cardiac output at rest in Laennec's cirrhosis. J Clin Invest. 1953;32:1025–33. Kowalski HJ, Abelmann WH. The cardiac output at rest in Laennec's cirrhosis. J Clin Invest. 1953;32:1025–33.
2.
go back to reference Krag A, Bendtsen F, Henriksen JH, Møller S. Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites. Gut. 2010;59:105–10.CrossRefPubMed Krag A, Bendtsen F, Henriksen JH, Møller S. Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites. Gut. 2010;59:105–10.CrossRefPubMed
3.
go back to reference Fouad TR, Abdel-Razek WM, Burak KW, Bain VG, Lee SS. Prediction of cardiac complications after liver transplantation. Transplantation. 2009;87:763–70.CrossRefPubMed Fouad TR, Abdel-Razek WM, Burak KW, Bain VG, Lee SS. Prediction of cardiac complications after liver transplantation. Transplantation. 2009;87:763–70.CrossRefPubMed
4.
go back to reference Alexander J, Mishra P, Desai N, Ambadekar S, Gala B, Sawant P. Cirrhotic cardiomyopathy: Indian scenario. J Gastroenterol Hepatol. 2007;22:395–9.CrossRefPubMed Alexander J, Mishra P, Desai N, Ambadekar S, Gala B, Sawant P. Cirrhotic cardiomyopathy: Indian scenario. J Gastroenterol Hepatol. 2007;22:395–9.CrossRefPubMed
6.
go back to reference Rangari M, Sinha S, Kapoor D, Mohan JC, Sarin SK. Prevalence of autonomic dysfunction in cirrhotic and noncirrhotic portal hypertension. Am J Gastroenterol. 2002;97:707–13.CrossRefPubMed Rangari M, Sinha S, Kapoor D, Mohan JC, Sarin SK. Prevalence of autonomic dysfunction in cirrhotic and noncirrhotic portal hypertension. Am J Gastroenterol. 2002;97:707–13.CrossRefPubMed
7.
go back to reference Dadhich S, Goswami A, Jain VK, Gahlot A, Kulamarva G, Bhargava N. Cardiac dysfunction in cirrhotic portal hypertension with or without ascites. Ann Gastroenterol. 2014;27:244–9.PubMedPubMedCentral Dadhich S, Goswami A, Jain VK, Gahlot A, Kulamarva G, Bhargava N. Cardiac dysfunction in cirrhotic portal hypertension with or without ascites. Ann Gastroenterol. 2014;27:244–9.PubMedPubMedCentral
8.
go back to reference Perumal TP. Prevalence of cirrhotic cardiomyopathy. Univ J Med Med Spec. 2016;2:1–6. Perumal TP. Prevalence of cirrhotic cardiomyopathy. Univ J Med Med Spec. 2016;2:1–6.
9.
go back to reference Shukla A, Bhatt P, Gupta DK, et al. Cirrhotic cardiomyopathy is less prevalent in patients with Budd-Chiari syndrome than cirrhosis of liver. Indian J Gastroenterol. 2017;36:474–80. Shukla A, Bhatt P, Gupta DK, et al. Cirrhotic cardiomyopathy is less prevalent in patients with Budd-Chiari syndrome than cirrhosis of liver. Indian J Gastroenterol. 2017;36:474–80.
10.
go back to reference Sakthi S, Kumar S, Rajasigamani A, Socrates. Prevalence of cirrhotic cardiopathy in patients with cirrhosis of liver: a tertiary hospital experience. Int J Pharm Bio Sci. 2017;8:298–303. Sakthi S, Kumar S, Rajasigamani A, Socrates. Prevalence of cirrhotic cardiopathy in patients with cirrhosis of liver: a tertiary hospital experience. Int J Pharm Bio Sci. 2017;8:298–303.
11.
go back to reference Thirumal P, Muthukumaran RG, Balamurali GP, Kumar SJ. Prevalence of cirrhotic cardiomyopathy—our center experience. J Clin Exp Hepatol. 2014;4:S84. Thirumal P, Muthukumaran RG, Balamurali GP, Kumar SJ. Prevalence of cirrhotic cardiomyopathy—our center experience. J Clin Exp Hepatol. 2014;4:S84.
12.
go back to reference Patil S, Lal B, Pandey M, Haldia SS, Rishi JP. A clinical study of cardiovascular dysfunction in patients of cirrhosis of liver. Ann Int Med Den Res. 2016;2:212–5. Patil S, Lal B, Pandey M, Haldia SS, Rishi JP. A clinical study of cardiovascular dysfunction in patients of cirrhosis of liver. Ann Int Med Den Res. 2016;2:212–5.
13.
14.
go back to reference Daniel WW. Biostatistics: A Foundation for Analysis in the Health Sciences. John W, & Sons, Inc. Hoboken. 1999;8:189–90. Daniel WW. Biostatistics: A Foundation for Analysis in the Health Sciences. John W, & Sons, Inc. Hoboken. 1999;8:189–90.
15.
go back to reference Barbosa M, Guardado J, Marinho C, et al. Cirrhotic cardiomyopathy: isn’t stress evaluation always required for the diagnosis? World J Hepatol. 2016;8(3):200–6. Barbosa M, Guardado J, Marinho C, et al. Cirrhotic cardiomyopathy: isn’t stress evaluation always required for the diagnosis? World J Hepatol. 2016;8(3):200–6.
16.
go back to reference Torregrosa M, Aguadé S, Dos L, et al. Cardiac alterations in cirrhosis: reversibility after liver transplantation. J Hepatol. 2005;42:68–74. Torregrosa M, Aguadé S, Dos L, et al. Cardiac alterations in cirrhosis: reversibility after liver transplantation. J Hepatol. 2005;42:68–74.
17.
go back to reference Karagiannakis DS, Papatheodoridis G, Vlachogiannakos J. Recent advances in cirrhotic cardiomyopathy. Dig Dis Sci. 2015;60:1141–51.CrossRefPubMed Karagiannakis DS, Papatheodoridis G, Vlachogiannakos J. Recent advances in cirrhotic cardiomyopathy. Dig Dis Sci. 2015;60:1141–51.CrossRefPubMed
18.
go back to reference Zambruni A, Di Micoli A, Lubisco A, Domenicali M, Trevisani F, Bernardi M. QT interval correction in patients with cirrhosis. J Cardiovasc Electrophysiol. 2007;18:77–82.CrossRefPubMed Zambruni A, Di Micoli A, Lubisco A, Domenicali M, Trevisani F, Bernardi M. QT interval correction in patients with cirrhosis. J Cardiovasc Electrophysiol. 2007;18:77–82.CrossRefPubMed
19.
go back to reference Ruiz-del-Árbol L, Serradilla R. Cirrhotic cardiomyopathy. World J Gastroenterol. 2015;21:11502–21. Ruiz-del-Árbol L, Serradilla R. Cirrhotic cardiomyopathy. World J Gastroenterol. 2015;21:11502–21.
20.
go back to reference Boudina S, Abel ED. Diabetic cardiomyopathy, causes and effects. Rev Endocr Metab Disord. 2010;11:31–9. Boudina S, Abel ED. Diabetic cardiomyopathy, causes and effects. Rev Endocr Metab Disord. 2010;11:31–9.
21.
go back to reference Kuroda K, Tomoko S, Amano A. Hypertensive cardiomyopathy: a clinical approach and literature review. World J Hypertens. 2015;5:41–52. Kuroda K, Tomoko S, Amano A. Hypertensive cardiomyopathy: a clinical approach and literature review. World J Hypertens. 2015;5:41–52.
22.
go back to reference Fernandez-Sola J, Estruch R, Grau JM, Pare JC, Rubin E, Urbano-Marquez A. The relation of alcoholic myopathy to cardiomyopathy. Ann Intern Med. 1994;120:529–36.CrossRefPubMed Fernandez-Sola J, Estruch R, Grau JM, Pare JC, Rubin E, Urbano-Marquez A. The relation of alcoholic myopathy to cardiomyopathy. Ann Intern Med. 1994;120:529–36.CrossRefPubMed
23.
go back to reference Ingles AC, Hernandez I, Garcia-Estan J, et al. Limited cardiac preload reserve in conscious cirrhotic rats. Am J Phys. 1991;260:1912–7. Ingles AC, Hernandez I, Garcia-Estan J, et al. Limited cardiac preload reserve in conscious cirrhotic rats. Am J Phys. 1991;260:1912–7.
24.
go back to reference Harcombe AA, Ramsay L, Kenna JG, et al. Circulating antibodies to cardiac protein-acetaldehyde adducts in alcoholic heart muscle disease. Clin Sci. 1995;88:263–8. Harcombe AA, Ramsay L, Kenna JG, et al. Circulating antibodies to cardiac protein-acetaldehyde adducts in alcoholic heart muscle disease. Clin Sci. 1995;88:263–8.
Metadata
Title
Prevalence and clinical presentation of cirrhotic cardiomyopathy: A single centre experience from southern India
Authors
Ravi Bokarvadia
Mayank Jain
Chandankumar Kedarisetty
Joy Varghese
Jayanthi Venkataraman
Publication date
01-04-2019
Publisher
Springer India
Published in
Indian Journal of Gastroenterology / Issue 2/2019
Print ISSN: 0254-8860
Electronic ISSN: 0975-0711
DOI
https://doi.org/10.1007/s12664-019-00946-7

Other articles of this Issue 2/2019

Indian Journal of Gastroenterology 2/2019 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.